Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VNDA
VANDA PHARMACEUTICALS INC.
NASDAQ
$5.29
▼ DOWN 2.76% (-0.15)

KEY STATISTICS

Market Cap$318.12 M
52w High$9.94
52w Low$4.27
Dividend Yield—
Frequency—
P/E-1.14
Volume525.25K
Shares Out.60.14M

COMPANY

LEADERSHIP

Mihael H. Polymeropoulos
CHIEF EXECUTIVE
Mihael H. Polymeropoulos

COMPENSATION 2026

Salary$965,655
Stock Awards$2,007,000
Incentive Plan Pay$834,326
All Other Comp.$44,487
Total$3,851,468

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 12, 2006
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
533

PRICE TARGET

Target High$21.00
Target Low$21.00
Target Median$21.00
Target Consensus$21.00

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$69.30M
NOV
4
WED

PRICE

$5.29 ▼ DOWN 2.76% (−$0.15)
$5.25$5.33$5.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.29

About Vanda Pharmaceuticals Inc.

https://www.vandapharma.com ↗

Vanda Pharmaceuticals Inc. develops and markets therapies for high unmet medical needs, including sleep disorders and schizophrenia, with a diverse pipeline targeting neurological, psychiatric, and other conditions globally.

INDUSTRY

Biotechnology

A PRODUCT VANDA PHARMACEUTICALS INC. IS KNOWN FOR

NEREUS™ (tradipitant)
NEREUS™ (tradipitant)

NEREUS™ is an FDA-approved NK-1 receptor antagonist for motion-induced vomiting, with ongoing development for other uses, highlighting Vanda's focus on innovative therapies.

COMPETITORS

COMPETITOR
ABBV COMPARE
PFE COMPARE
RYTM COMPARE
TBPH COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Fanapt$31.25M $33.22M ▲$29.56M ▼$35.99M ▲
Hetlioz$17.98M $16.39M ▼$15.95M ▼$5.58M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
111
LISTED HERE
23
RANKED BY POSITION SIZE
XBI
0.11% · 2.4M
VTS.AX
0.00% · 1.8M
XSU.TO
0.01% · 1.4M
SCHA
0.01% · 283.6K
FESM
0.02% · 219.2K
DFMC
0.01% · 198.2K
AVSC
0.02% · 134.8K
FSCC
0.20% · 124.9K
PRFZ
0.02% · 111.5K
LABU
0.08% · 88.8K
GSSC
0.04% · 83.1K
HAPS
0.16% · 52.0K
XRSU.L
0.01% · 49.2K
JPSE
0.03% · 38.2K
RSSL
0.01% · 25.5K
MEDX
0.63% · 20.5K
SQLV
0.12% · 9.3K
RFLR
0.04% · 7.7K
ASD
2.07% · 5.4K
URTY
0.00% · 2.2K
DM
DMRS
0.08% · 1.6K
VETS
0.03% · 1.4K
RESM
0.01% · 111

INSTITUTIONAL OWNERSHIP

SHARES OWNED
78.42%
HOLDERS
279
TOP 12 OF 279 · RANKED BY POSITION SIZE
Blackrock, Inc.
8.9M sh · $44.5M
Blackrock Inc.
8.1M sh · $45.98M
Renaissance Technologies LLC
3.8M sh · $25.98M
Vanguard Group Inc
3.7M sh · $32.91M
State Street Corp
3.5M sh · $21.52M
Aqr Capital Management LLC
3.5M sh · $21.41M
Millennium Management LLC
3.3M sh · $16.22M
Aigh Capital Management LLC
2.8M sh · $19M
Dimensional Fund Advisors LP
2.6M sh · $12.79M
Acadian Asset Management LLC
2.4M sh · $21.25M
Tang Capital Management LLC
2.4M sh · $11.74M
Blackrock Fund Advisors
2.3M sh · $36.21M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Honore Tage
Purchase · 41.6K shares
2026-06-04
★
OFFICER: SVP, GC AND SECRETARY
McGuire Daniel Patrick
Purchase · 80.0K shares
2026-06-04
★
DIRECTOR
Chrousos Phaedra
Purchase · 41.6K shares
2026-06-04
★
DIRECTOR
Duncan Charles Cliff
Purchase · 41.6K shares
2026-06-04

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
HOLD 1
OVERWEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
B. Riley Securities BUY HC Wainwright & Co. BUY Jefferies HOLD Cantor Fitzgerald OVERWEIGHT

SECTORS PEERS

PEERPRICE
ACHV$8.10COMPARE
ALLO$2.02COMPARE
CAPR$9.59COMPARE
ARCT$15.19COMPARE
AVIR$5.36COMPARE
SGMT$10.55COMPARE
TRDA$7.00COMPARE
VYGR$3.54COMPARE